JP2017528454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528454A5 JP2017528454A5 JP2017511933A JP2017511933A JP2017528454A5 JP 2017528454 A5 JP2017528454 A5 JP 2017528454A5 JP 2017511933 A JP2017511933 A JP 2017511933A JP 2017511933 A JP2017511933 A JP 2017511933A JP 2017528454 A5 JP2017528454 A5 JP 2017528454A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- pharmaceutical composition
- composition according
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/473,339 | 2014-08-29 | ||
| US14/473,339 US9890200B2 (en) | 2011-04-12 | 2014-08-29 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| PCT/US2015/047390 WO2016033432A1 (en) | 2014-08-29 | 2015-08-28 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528454A JP2017528454A (ja) | 2017-09-28 |
| JP2017528454A5 true JP2017528454A5 (enExample) | 2018-10-04 |
Family
ID=52583553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511933A Pending JP2017528454A (ja) | 2014-08-29 | 2015-08-28 | 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9890200B2 (enExample) |
| EP (1) | EP3185883A4 (enExample) |
| JP (1) | JP2017528454A (enExample) |
| KR (1) | KR20170044171A (enExample) |
| CN (1) | CN107073075A (enExample) |
| AU (1) | AU2015308761A1 (enExample) |
| BR (1) | BR112017003731A2 (enExample) |
| CA (1) | CA2958085A1 (enExample) |
| MX (1) | MX2017002476A (enExample) |
| RU (1) | RU2017110093A (enExample) |
| SG (1) | SG11201701135WA (enExample) |
| WO (1) | WO2016033432A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| KR20170102900A (ko) * | 2015-01-08 | 2017-09-12 | 모레 매트릭스 인코포레이티드 | Mk2 저해제 펩타이드의 제형 |
| CA2978941A1 (en) * | 2015-03-12 | 2016-09-15 | Moerae Matrix, Inc. | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same |
| CN112920256B (zh) * | 2019-11-21 | 2022-08-19 | 上海医药工业研究院 | 一种治疗哮喘的生物肽及其应用 |
| EP4464694A4 (en) | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| DK172541B1 (da) | 1982-10-08 | 1998-12-07 | Glaxo Group Ltd | Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet |
| AU591152B2 (en) | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| AU4115693A (en) | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| DK0733059T3 (da) | 1993-12-09 | 2000-10-16 | Univ Jefferson | Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler |
| ES2130597T3 (es) * | 1994-02-17 | 1999-07-01 | American Home Prod | Derivados de bifenilo sustituido como inhibidores de la fosfodiesterasa. |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| DK1165050T3 (da) | 1999-04-05 | 2006-05-01 | Mannkind Corp | Fremgangsmåde til dannelse af fint pulver |
| ES2395096T3 (es) | 1999-06-29 | 2013-02-08 | Mannkind Corporation | Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas |
| NZ536796A (en) | 2002-04-25 | 2007-03-30 | Scripps Research Inst | Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant |
| US20040131614A1 (en) | 2002-07-19 | 2004-07-08 | Abbott Biotechnology Ltd. | Treatment of pulmonary disorders using TNFalpha inhibitor |
| MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| BRPI0514410A (pt) | 2004-08-23 | 2008-06-10 | Mannkind Corp | fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5 |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| RU2008142388A (ru) * | 2006-04-03 | 2010-05-10 | Тева Фармасьютикл Индастриес Лтд. (Il) | Микрочастицы лекарственного вещества |
| ES2594281T3 (es) | 2007-01-10 | 2016-12-19 | Purdue Research Foundation | Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos |
| US8063094B2 (en) | 2007-02-08 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
| US20080282320A1 (en) | 2007-05-11 | 2008-11-13 | Denovo Andrew | Security Compliance Methodology and Tool |
| DK2185698T3 (en) | 2007-08-07 | 2015-07-27 | Purdue Research Foundation | Kinase Inhibitors and Uses thereof |
| CN102256613B (zh) | 2008-10-20 | 2014-09-10 | 莫伊莱麦屈克斯公司 | 用于治疗或者预防粘连的多肽 |
| AU2013202108B2 (en) * | 2008-12-10 | 2015-12-24 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US9327008B2 (en) | 2008-12-10 | 2016-05-03 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| EP2575855A4 (en) | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| CN108014340A (zh) * | 2011-04-12 | 2018-05-11 | 莫伊莱麦屈克斯公司 | 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法 |
-
2014
- 2014-08-29 US US14/473,339 patent/US9890200B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 SG SG11201701135WA patent/SG11201701135WA/en unknown
- 2015-08-28 RU RU2017110093A patent/RU2017110093A/ru not_active Application Discontinuation
- 2015-08-28 AU AU2015308761A patent/AU2015308761A1/en not_active Abandoned
- 2015-08-28 MX MX2017002476A patent/MX2017002476A/es unknown
- 2015-08-28 BR BR112017003731A patent/BR112017003731A2/pt not_active IP Right Cessation
- 2015-08-28 CA CA2958085A patent/CA2958085A1/en not_active Abandoned
- 2015-08-28 JP JP2017511933A patent/JP2017528454A/ja active Pending
- 2015-08-28 EP EP15835631.1A patent/EP3185883A4/en not_active Withdrawn
- 2015-08-28 WO PCT/US2015/047390 patent/WO2016033432A1/en not_active Ceased
- 2015-08-28 CN CN201580058532.3A patent/CN107073075A/zh active Pending
- 2015-08-28 KR KR1020177007622A patent/KR20170044171A/ko not_active Withdrawn
-
2017
- 2017-12-27 US US15/855,398 patent/US10562947B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533235A5 (enExample) | ||
| RU2013150249A (ru) | Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса | |
| JP6889201B2 (ja) | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 | |
| US20130216608A1 (en) | Airway Administration of Angiogenesis Inhibitors | |
| JP2014169332A (ja) | 肺疾患を処置するためのモノクローナル抗体の霧状化 | |
| JP2014521684A5 (enExample) | ||
| JP2002539072A5 (enExample) | ||
| JP2017509633A5 (enExample) | ||
| JP2015505303A5 (enExample) | ||
| CN101848733A (zh) | 用于肺部给予TNFα抑制剂的方法和组合物 | |
| CN103429610B (zh) | 用于抑制炎症的肽 | |
| JP2016516016A5 (enExample) | ||
| RU2017110093A (ru) | Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса | |
| JP2002541213A5 (enExample) | ||
| JP2010539243A (ja) | 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤 | |
| Li et al. | Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization | |
| JP2004500844A (ja) | Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法 | |
| JP2020501510A5 (enExample) | ||
| CN106075401A (zh) | 白介素35在制备治疗自身免疫性皮肤病药物中的用途和治疗药物以及IL‑35‑Fc融合蛋白 | |
| RU2016140332A (ru) | Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл) | |
| Wang et al. | The effects of aerosolized STAT1 antisense oligodeoxynucleotides on rat pulmonary fibrosis | |
| CN117209612A (zh) | 融合蛋白及其应用 | |
| Laurina et al. | Growth factors/cytokines/defensins and apoptosis in periodontal pathologies | |
| Liu et al. | Muscarinic acetylcholine receptor antagonist darifenacin protects against pulmonary fibrosis through ERK/NF-κB/miR-21 pathway | |
| Xin et al. | Protein and Peptide Delivery to the Lung via Inhalation |